


 SENDERRA Specialty Pharmacy 3712 E. Plano Parkway, Ste. 200 Plano, TX 75074 <i>This prescription form is to be sent & received via fax</i>	Pediatric Dermatology Enrollment Form A-D		Prescriber:	NPI:
			Supervising Physician:	NPI:
			Address:	Tax ID:
			Phone:	Fax:
			Contact:	
Physician Offices Call: 855-460-7928				
Fax: 888-777-5645				

PATIENT INFORMATION				
Name:	☐ M ☐ F ☐ Trans M ☐ Trans F ☐ Other	DOB: ____/____/____	SS#: ____-____-____	
Street:	City:	State:	ZIP:	
Phone:	Alt. Phone:	☐ English ☐ Spanish ☐ Other: _____	Wt.: _____	Ht.: _____

PRESCRIPTION				
Has the patient received a loading dose/starter kit? ☐ Yes Start Date: ____/____/____ ☐ No SHIP TO: ☐ Patient's Home ☐ Doctor's Office ☐ Other: _____				
Drug		Directions & Quantity	Refills	
Cosentyx®	☐ 75 mg Pre-filled Syringe	☐ INITIAL: Inject 75 mg SQ at week 0, 1, 2, 3, and 4 (Quantity: 5) ***WEIGHT REQUIRED*** ☐ MAINTENANCE: Inject 75 mg SQ every 4 weeks (Quantity: 1) ***Intended for weight < 50 kg/110 lbs***		
	☐ 150 mg Sensoready® Pen	☐ INITIAL: Inject 150 mg SQ at week 0, 1, 2, 3, and 4 (Quantity: 5) ***Intended for patients with plaque psoriasis weight ≥ 50 kg/110 lbs and patients with hidradenitis suppurativa weight ≥ 30 kg/66 lbs to <90 kg/198 lbs*** ☐ MAINTENANCE: Inject 150 mg SQ every 4 weeks (Quantity: 1)		
	☐ 150 mg Pre-filled Syringe			
	☐ Sensoready® Pen	☐ INITIAL: Inject 300 mg SQ at week 0, 1, 2, 3, and 4 (Quantity: QS 5 doses) ☐ MAINTENANCE: Inject 300 mg SQ every 4 weeks (Quantity: QS 28 days) ***Intended for patients with hidradenitis suppurativa weight ≥ 90 kg/198 lbs		
	☐ UnoReady® Pen			
	☐ Pre-filled Syringe			
Dupixent®		PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE: ***WEIGHT REQUIRED***		
		☐ INITIAL: Inject 600 mg SQ (two 300 mg injections) at week 0 (Quantity: 2) ☐ MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2) ***Intended for weight ≥ 60 kg/132 lbs***		
		☐ INITIAL: Inject 400 mg SQ (two 200 mg injections) at week 0 (Quantity: 2) ☐ MAINTENANCE: Inject 200 mg SQ every other week starting at day 15 (Quantity: 2) ***Intended for weight 30 kg/66 lbs to <60 kg/132 lbs***		
		☐ INITIAL: Inject 600 mg SQ (two 300 mg injections) at week 0 (Quantity: 2) ☐ MAINTENANCE: Inject 300 mg SQ every 4 weeks thereafter (Quantity: 1) ***Intended for weight 15 kg/33 lbs to <30 kg/66 lbs***		
		PEDIATRIC PATIENTS 2 TO 5 YEARS OF AGE:		
		☐ Inject 200 mg SQ every 4 weeks (Quantity: 1) ***Intended for weight 5 kg/11 lbs to <15 kg/33 lbs***		
		☐ Inject 300 mg SQ every 4 weeks (Quantity: 1) ***Intended for weight 15 kg/33 lbs to <30 kg/66 lbs***		

MEDICAL INFORMATION				
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY				
PREVIOUS THERAPIES: ☐ Methotrexate ☐ Humira ☐ Enbrel ☐ _____	Tried & Failed (Duration): ☐ (_____)	Not Tolerated: ☐	Contraindication: _____ _____ _____	 Affected Areas ☐ Face ☐ Feet ☐ Groin ☐ Nails ☐ Scalp ☐ Other: _____ BSA _____%
PHOTOTHERAPY ☐ UVA /UVB ☐ Patient cannot afford	Tried & Failed (Duration): ☐ (_____)	Not Tolerated: ☐	Contraindication: ☐ Distance from Office	
Date of Diagnosis: ____/____/____ Allergies: _____ ☐ L40.0 Psoriasis Vulgaris (Plaque Psoriasis) ☐ L50.8 Other Urticaria ☐ L73.2 Hidradenitis suppurativa ☐ Other: _____				
Active TB ruled out: ☐ Yes ☐ No Date: ____/____/____ Active Hep B ruled out: ☐ Yes ☐ No Date: ____/____/____				
Additional Clinical Information: _____ _____ _____				

American Academy of Dermatology Consensus Statement on Psoriasis Therapies	
☐ Psoriasis is covering greater than 10% of body surface area ☐ Psoriasis is on palms, soles, head and neck, or genitalia ☐ Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints ☐ Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships	
INJECTION TRAINING	
☐ Patient has received pen and injection training ☐ Physician's office to provide injection training ☐ Senderra to coordinate injection training	
PRESCRIBER SIGNATURE	
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.	
Prescriber: _____	Date: ____/____/____
CONFIDENTIALITY NOTICE	
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.	